In addition, peripheral neuropathy evoked by oxaliplatin, a platinum-based chemotherapeutic agent, has been linked to activation of HCN channels-mediated currents (Ih), and ivabradine can attenuate this effect (Chang et al., 2020). Here, MALAT1 is linked to peripheral neuropathy.